The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index; none of the 73 sources its claims cite is checked for support yet.
Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins
Open accessAbstract
Human papillomaviruses (HPV) are believed to be the primary causal agents for development of pre‐neoplastic and malignant lesions of the uterine cervix, and high‐risk types such as type 16 and 18 are associated with more than 90% of all cervical carcinomas. The E6 and E7 genes of HPV are thought to play causative roles, since E6 promotes the degradation of p53 through its interaction with E6AP, an E3 ubiquitin ligase, whereas E7 binds to the retinoblastoma protein (pRb) and disrupts its complex formation with E2F transcription factors. Although prophylactic vaccines have become available, it is still necessary to clarify the mechanisms of HPV‐induced carcinogenesis because of the widespread nature of HPV infection. Approximately 493 000 new cases of cervical cancer are diagnosed each year with approximately 274 000 mortalities due to invasive cervical cancer. In the present article, the mechanisms of HPV16 E6‐ and E7‐induced multistep carcinogenesis and recently identified functions of these onco‐proteins are reviewed. (Cancer Sci 2007; 98: 1505–1511)
Overview
CoChat Summary
Written by AI from the paper’s full text.
TL;DR
This review summarizes how high-risk HPV E6 and E7 oncoproteins drive cervical carcinogenesis by inactivating p53 and pRb family proteins and by targeting additional cellular pathways. It emphasizes that overexpression of E6/E7, usually after viral integration, is a bottleneck step that cooperates with further genetic and epigenetic changes.
Key findings
- High-risk HPV types (16, 18, 31, 33, 45, 51, 52, 58, etc.) are associated with more than 90% of cervical cancers; HPV16 accounts for approximately half and HPV18 for another 10–20%. Approximately 493,000 new cervical cancer cases and 274,000 deaths occur annually.
- E6 promotes degradation of p53 through interaction with E6AP, an E3 ubiquitin ligase, while E7 binds pRb family proteins and disrupts pRb–E2F complexes; together they cause polyploidy and genomic instability.
- E6 has p53-independent functions, including hTERT/telomerase induction and degradation of PDZ-domain proteins such as DLG, Scribble, MUPP1, MAGI-1/-2/-3, GIPC, PATJ, PTPN3, and PSD95; E7 targets many proteins including p27, p21, p600, and PP2A.
- Integration and high-level E6/E7 expression are proposed as the bottleneck step; additional events reported in cervical cancers include PIK3CA, c-myc, ErbB2, and cIAP1 amplification, ras mutation, and decreased PTEN and TSLC1 expression.
Methods
- Narrative review; no primary experimental data, sample, or systematic analysis are reported.
- Synthesizes published literature and the authors’ recent work on HPV16 E6- and E7-induced multistep carcinogenesis, the HPV life cycle, and target proteins of E6 and E7 (Table 1; Figs 1–5).
Limitations
- The paper does not state formal limitations; it notes that further exploration is needed for TSC2/Tuberin as a possible E6 target.
- Evident from the text: this is a narrative review without stated systematic search or inclusion criteria, and some mechanistic claims rely on cited reviews, speculation, or a personal communication (A. Suhrbier, 2007) regarding E7-mediated pRb cleavage.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
57 Sources not found · 14 Own interpretation
In the paper
“The most manifest function of the E6 protein is to promote the degradation of p53 through its interaction with a cellular protein, E6 associated protein (E6AP), an E3 ubiquitin ligase (9)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“in the presence of E6, a repressor complex of TERT promoter, containing USF1 and USF2, is replaced by Myc, which corresponds to higher levels of TERT transcription and consequently, telomerase activity.(35)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
What the sources say
- Not matchedcites [35]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“The interaction of E7 with cyclin-dependent kinase (CDK)2/cyclin A, (60) as well as CDK2/cyclin E, (61) has also been reported.”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > IRF1
What the sources say
- Not matchedcites [60]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“For evasion of the immune system, E7 also interacts with p48, (64) as well as IRF1.(8)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > IRF1
What the sources say
- Not matchedcites [64]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“E6 and Myc interaction has been shown to activate the telomerase reverse transcriptase promoter, (34)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
What the sources say
- Not matchedcites [34]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
- Probably not a substantial claim. 9
- It may state two separate claims as one. 18
Create a free account to see these claims.
Create a free account to see these assumptions.
42 more claims
Create a free account to see all 71 claims and every source verdict.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > Tyk2
“TSC2 (tubulin)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
“The tumor suppressor gene TSC2 product, Tuberin”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > HPV infection and HPV-induced transformation
“The ultimate development of cervical cancer is rarely accompanied by high expression of E6 and E7 proteins.”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > HPV infection and HPV-induced transformation
“CIN III (severe dysplasia, carcinoma in situ) and invasive cancer lesions often display high-level expression of E6 and E7”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
“Therefore, its down regulation through p53 with E6/E6AP has been revealed as a novel tumor suppressor mechanism blocking development of HPV-induced cervical carcinogenesis.”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
“its down-regulation by E6 might contribute to the development of cervical cancer.”
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Papillomaviruses and cancer: from basic studies to clinical application
Hausen, H. Z. (2002) · Nature reviews. Cancer · doi:10.1038/nrc798 · Cited by 4,094
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Ellisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., & Sklar, J. (1991) · Cell · doi:10.1016/0092-8674(91)90111-b · Cited by 1,691
Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer
Storey, A., Thomas, M., Kalita, A., Harwood, C. A., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., & Banks, L. (1998) · Nature · doi:10.1038/30400 · Cited by 971
Notch1 functions as a tumor suppressor in mouse skin
Nicolas, M., Wolfer, A., Raj, K., Kummer, J. A., Mill, P., van Noort, M., Hui, C., Clevers, H. C., Dotto, G. P., & Radtke, F. (2003) · Nature Genetics · doi:10.1038/ng1099 · Cited by 969
Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation
Rangarajan, A., Talora, C., Okuyama, R., Nicolas, M., Mammucari, C., Oh, H., Aster, J. C., Krishna, S., METZGER, D., Chambon, P., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3427 · Cited by 867
The Ets family of transcription factors
Wasylyk, B., Hahn, S. L., & Giovane, A. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb19864.x · Cited by 839
Mechanisms of human papillomavirus-induced oncogenesis
Münger, K., Baldwin, A., Edwards, K. M., Hayakawa, H., Nguyen, C. L., Owens, M., Grace, M., & Huh, K. (2004) · Journal of Virology · doi:10.1128/jvi.78.21.11451-11460.2004 · Cited by 815
Telomerase activation by the E6 gene product of human papillomavirus type 16
Klingelhutz, A. J., Foster, S. A., & McDougall, J. K. (1996) · Nature · doi:10.1038/380079a0 · Cited by 660
Cited by
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
The HECT Family of E3 Ubiquitin Ligases: Multiple Players in Cancer Development
Bernassola, F., Karin, M., Ciechanover, A., & Melino, G. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.001 · Cited by 541
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Wang, R., Pan, W. D., Lei, J., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.039 · Cited by 530
Enhanced Protein Degradation by Branched Ubiquitin Chains
Meyer, H., & Rapé, M. (2014) · Cell · doi:10.1016/j.cell.2014.03.037 · Cited by 500
Papillomavirus E6 oncoproteins
Pol, S. V., & Klingelhutz, A. J. (2013) · Virology · doi:10.1016/j.virol.2013.04.026 · Cited by 374
Regulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
Li, J., Poi, M. J., & Tsai, M. (2011) · Biochemistry · doi:10.1021/bi200642e · Cited by 355
Esmaeili, M., Mohabatkar, H., & Mohsenzadeh, S. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.016 · Cited by 271
Yugawa, T., & Kiyono, T. (2009) · Reviews in Medical Virology · doi:10.1002/rmv.605 · Cited by 243
Self-citationRegulation of cellular miRNA expression by human papillomaviruses
Zheng, Z., & Wang, X. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.05.005 · Cited by 232
Li, S., Ma, Y., Zheng, P., & Zhang, P. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0744-0 · Cited by 226
Epigenetics and cervical cancer: from pathogenesis to therapy
Fang, J., Zhang, H., & Su-fang, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-1737-z · Cited by 225
Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer
Faridi, R., Zahra, A., Khan, K., & Idrees, M. (2011) · Virology Journal · doi:10.1186/1743-422x-8-269 · Cited by 198
Saha, S. S., Mandal, P., Sadhukhan, T., Chowdhury, R. R., Mondal, N. R., Chakravarty, B., Chatterjee, T., Roy, S. S., & Sengupta, S. (2015) · Scientific Reports · doi:10.1038/srep11724 · Cited by 196
FOXM1 (Forkhead box M1) in Tumorigenesis
Wierstra, I. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 191
Involvement of Human Papillomaviruses in Cervical Cancer
Wang, X., Huang, X., & Zhang, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02896 · Cited by 189
Cai, H., Yan, L., Liu, N., Xu, M. M., & Cai, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109790 · Cited by 186
Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines
Oyouni, A. A. A. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.02.014 · Cited by 182
E3 ubiquitin ligases in cancer and implications for therapies
Wang, D., Ma, L., Wang, B., Liu, J., & Wei, W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9703-z · Cited by 177
Carcinogenesis and management of human papillomavirus-associated cervical cancer
Kusakabe, M., Taguchi, A., Sone, K., Mori, M., & Osuga, Y. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02337-7 · Cited by 164
Lazarczyk, M., Cassonnet, P., Pons, C., Jacob, Y., & Favre, M. (2009) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00033-08 · Cited by 131
Emerging Functions of Human IFIT Proteins in Cancer
Pidugu, V. K., Pidugu, H. B., Wu, M., Liu, C., & Lee, T.-C. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00148 · Cited by 158
New Technologies and Procedures for Cervical Cancer Screening
Cuzick, J. M., Bergeron, C., Doeberitz, M. V. K., Gravitt, P. E., Jerónimo, J., Lorincz, A. T., Meijer, C. J. L. M., Sankaranarayanan, R., Snijders, P. J. F., & Szarewski, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.088 · Cited by 155
MicroRNA in Cervical Cancer: OncomiRs and Tumor Suppressor miRs in Diagnosis and Treatment
Banno, K., Iida, M., Yanokura, M., Kisu, I., Iwata, T., Tominaga, E., Tanaka, K., & Aoki, D. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/178075 · Cited by 147
Antioxidants in cervical cancer: Chemopreventive and chemotherapeutic effects of polyphenols
Domenico, F. D., Foppoli, C., Coccia, R., & Marzia Perluigi, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.005 · Cited by 144
HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53
Kwok (2010) · Oncology Reports · doi:10.3892/or_00001023 · Cited by 140
Asiaf, A., Ahmad, S. T., Mohammad, S. O., & Zargar, M. A. (2013) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e328364f273 · Cited by 132
TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy
Hu, Z., Ding, W., Zhu, D., Yu, L., Jiang, X., Wang, X., Zhang, C., Wang, L., Ji, T., Liu, D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78206 · Cited by 130
Resveratrol induces cell death in cervical cancer cells through apoptosis and autophagy
García‐Zepeda, S. P., García-Villa, E., Díaz‐Chávez, J., Hernández‐Pando, R., & Gariglio, P. (2013) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e328360345f · Cited by 129
Maher, D. M., Bell, M. C., O'Donnell, E. A., Gupta, B. K., Jaggi, M., & Chauhan, S. C. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20695 · Cited by 124
Olthof, N. C., Huebbers, C. U., Kolligs, J., Henfling, M. E. R., Ramaekers, F. C. S., Cornet, I., Albrechts, J. C. M., Stegmann, A. P. A., Silling, S., Wieland, U., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29112 · Cited by 120
Immunotherapy and targeted therapy for cervical cancer: an update
Menderes, G., Black, J., Schwab, C. L., & Santin, A. D. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1121108 · Cited by 120
Host and Microbiome Interplay Shapes the Vaginal Microenvironment
Kwon, M. S., & Lee, H. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.919728 · Cited by 120
Jiang, S., & Dong, Y. Q. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.02.006 · Cited by 118
CRISPR/Cas9‑mediated cervical cancer treatment targeting human papillomavirus E6
Yoshiba, T., Saga, Y., Urabe, M., Uchibor, R., Matsubara, S., Fujiwara, H., & Mizukami, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9815 · Cited by 115
Cellular binding partners of the human papillomavirus E6 protein
Tungteakkhun, S. S., & Duerksen-Hughes, P. J. (2008) · Archives of Virology · doi:10.1007/s00705-007-0022-5 · Cited by 110
Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix
Saavedra, K., Brebi, P., & Roa, J. C. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-13 · Cited by 110
Li, B. H., Zhou, J., Ye, F., Cheng, X. D., Zhou, C. Y., Lu, W., & Xie, X. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.037 · Cited by 108
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy
Nakamura, M., Obata, T., Daikoku, T., & Fujiwara, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215482 · Cited by 106
Viral Oncogenes, Noncoding RNAs, and RNA Splicing in Human Tumor Viruses
Zheng, Z. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.730 · Cited by 106
Li, B., Hu, Y., Ye, F., Li, Y., Lv, W., & Xie, X. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181d63170 · Cited by 105
Olthof, N. C., Speel, E. M., Kolligs, J., Haesevoets, A. M., Henfling, M. E. R., Ramaekers, F. C. S., Preuss, S. F., Drebber, U., Wieland, U., Silling, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088718 · Cited by 105
Oxidative stress in female cancers
Calaf, G. M., Urzúa, U., Termini, L., & Aguayo, F. (2018) · Oncotarget · doi:10.18632/oncotarget.25323 · Cited by 104
Advances in the management of squamous cell carcinoma of the head and neck
Machiels, J., Lambrecht, M. L. F., Hanin, F., Duprez, T. P. J., Grégoire, V., Schmitz, S., & Hamoir, M. (2014) · F1000Prime Reports · doi:10.12703/p6-44 · Cited by 103
Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells
Roy, M., & Mukherjee, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.3.1403 · Cited by 103
Gao, G., Chernock, R. D., Gay, H. A., Thorstad, W. L., Zhang, T. R., Wang, H., Ma, X., Luo, Y., Lewis, J. S., & Wang, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.27739 · Cited by 101
Munagala, R., Aqil, F., Jeyabalan, J., & Gupta, R. C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.037 · Cited by 100
Derbie, A., Mekonnen, D. S., Woldeamanuel, Y., Ostade, X. V., & Abebe, T. (2020) · Infectious Agents and Cancer · doi:10.1186/s13027-020-0278-x · Cited by 94
Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
Hwang, J. K., Hong, J., & Yun, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228627 · Cited by 93
Bazzaro, M., Anchoori, R. K., Mudiam, M. K. R., Issaenko, O. A., Kumar, S. K., Karanam, B., Lin, Z., Vogel, R. I., Gavioli, R., Destro, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100589p · Cited by 90
Schmitz, S., Ang, K. K., Vermorken, J. B., Haddad, R. I., Suarez, C. M., Wolf, G. T., Hamoir, M., & Machiels, J.-P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.007 · Cited by 89
Ajiro, M., & Zheng, Z. (2015) · mBio · doi:10.1128/mbio.02068-14 · Cited by 88
Jain, M., Yadav, D., Jarouliya, U., Chavda, V. K., Yadav, A. K., Chaurasia, B. K., & Song, M. (2023) · Pathogens · doi:10.3390/pathogens12121380 · Cited by 87
Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies
Mulvany, N. J., Allen, D. G., & Wilson, S. M. (2008) · Pathology · doi:10.1080/00313020802035907 · Cited by 87
Aftab, M., Poojary, S. S., Seshan, V., Kumar, S., Agarwal, P., Tandon, S., Zutshi, V., & Das, B. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-89388-w · Cited by 86
Angiogenesis and antiangiogenic agents in cervical cancer
Tomao, F., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Zoratto, F., Panici, P. B., & Papa, A. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s68286 · Cited by 83
Treatment of metastatic cervical cancer: Future directions involving targeted agents
Díaz-Padilla, I., Monk, B. J., MacKay, H. J., & Oaknin, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.07.006 · Cited by 81
Human DNA Virus Exploitation of the MAPK-ERK Cascade
DuShane, J. K., & Maginnis, M. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143427 · Cited by 80
Unique microRNA expression profiles in cervical cancer.
Gőcze, K., Gombos, K., Juhász, K., Kovács, K., Kajtár, B., Benczik, M., Göcze, P., Patczai, B., Arany, I., & Ember, I. (2013) · PubMed · Cited by 79
Mirzayans, R., Andrais, B., Kumar, P., & Murray, D. L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050708 · Cited by 76
Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches
Sanami, S., Azadegan‐Dehkordi, F., Rafieian‐Kopaei, M., Salehi, M., Ghasemi‐Dehnoo, M., Mahooti, M., Alizadeh, M., & Bagheri, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-91997-4 · Cited by 76
Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State
Akhatova, A., Azizan, A., Atageldiyeva, K. K., Ashimkhanova, A., Marat, А., Iztleuov, Y. M., Suleimenova, A., Shamkeeva, S., & Aimagambetova, G. N. (2022) · Vaccines · doi:10.3390/vaccines10111912 · Cited by 76
Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review
Pezzuto, A., D’Ascanio, M., Rícci, A., Pagliuca, A., & Carico, E. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13651 · Cited by 75
Su, P.-H., Lin, Y.-W., Huang, R.-L., Liao, Y.-P., Lee, H.-Y., Wang, H.-C., Chao, T.-K., Chen, C.-K., Chan, M. W. Y., Chu, T.-Y., et al. (2012) · Oncogene · doi:10.1038/onc.2012.29 · Cited by 75
Gupta, S., & Gupta, S. (2015) · Indian Journal of Dentistry · doi:10.4103/0975-962x.155877 · Cited by 75
Human Papillomavirus 16 E6 Upregulates APOBEC3B via the TEAD Transcription Factor
Mori, S., Takeuchi, T., Ishii, Y., Yugawa, T., Kiyono, T., Nishina, H., & Kukimoto, I. (2017) · Journal of Virology · doi:10.1128/jvi.02413-16 · Cited by 75
Self-citationDrosophila as a Model for Infectious Diseases
Harnish, J. M., Link, N., & Yamamoto, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052724 · Cited by 73
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Chiu, M. K.-L., Armstrong, E. J. L., Jennings, V., Foo, S., Crespo-Rodriguez, E., Bozhanova, G., Patin, E. C., McLaughlin, M., Mansfield, D., Baker, G., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729351 · Cited by 72
Müller, E. E., Rebe, K. B., Chirwa, T. F., Struthers, H. E., McIntyre, J. A., & Lewis, D. A. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1706-9 · Cited by 72
Gao, D., Zhang, Y., Zhu, M., Liu, S., & Wang, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164701 · Cited by 70
HPV16 E6 augments Wnt signaling in an E6AP-dependent manner
Lichtig, H., Gilboa, D. A., Jackman, A., Gonen, P., Levav-Cohen, Y., Haupt, Y., & Sherman, L. (2010) · Virology · doi:10.1016/j.virol.2009.10.011 · Cited by 61
HPV Variants and HLA Polymorphisms: The Role of Variability on The Risk of Cervical Cancer
de Araujo‐Souza, P. S., Sichero, L. C., & Maciag, P. (2009) · Future Oncology · doi:10.2217/fon.09.8 · Cited by 70
Chen, C.-F., Chu, C.-Y., Chen, T.-H., Lee, S., Shen, C., & Hsiao, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020654 · Cited by 69
Gu, W., Yeo, E., McMillan, N. A. J., & Yu, C. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.58 · Cited by 69
Structure of the p53 degradation complex from HPV16
Wang, J. C. K., Baddock, H. T., Mafi, A., Foe, I. T., Bratkowski, M. A., Lin, T., Jensvold, Z. D., López, M. P., Stokoe, D., Eaton, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45920-w · Cited by 68
Sun, J., Xu, J., Liu, C., An, Y., Xu, M., Zhong, X., Zeng, N., Ma, S., He, H., Hu, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28208 · Cited by 66
Mirzayans, R., Andrais, B., Kumar, P., & Murray, D. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050928 · Cited by 66
Human Papillomavirus-Associated Cancers
Alhamlan, F. S., Al‐Fageeh, M. B., Mushait, M. A. A., Al-Badawi, I. A., & Al‐Ahdal, M. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-67452-6_1 · Cited by 64
Cervical Cancer Screening Recommendations: Now and for the Future
Rayner, M., Welp, A. M., Stoler, M. H., & Cantrell, L. A. (2023) · Healthcare · doi:10.3390/healthcare11162273 · Cited by 64
Shamanna, R. A., Hoque, M., Pe’ery, T., & Mathews, M. B. (2012) · Oncogene · doi:10.1038/onc.2012.533 · Cited by 64
Mirzayans, R., Andrais, B., Scott, A., Wang, Y., Kumar, P., & Murray, D. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020360 · Cited by 64
The Role of Human Papilloma Virus in Lung Cancer: A Review of the Evidence
Rezazadeh, A., Laber, D. A., Ghim, S., Jenson, A. B., & Kloecker, G. H. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181a393ba · Cited by 61
New molecular targets against cervical cancer
Dueñas‐González, A., Serrano‐Olvera, A., Cetina, L., & Coronel, J. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s49471 · Cited by 59
The Interplay between Antiviral Signalling and Carcinogenesis in Human Papillomavirus Infections
Ferreira, A., Ramalho, A. C., Marques, M., & Ribeiro, D. (2020) · Cancers · doi:10.3390/cancers12030646 · Cited by 58
DNA vaccination and gene therapy: optimization and delivery for cancer therapy
Bodles-Brakhop, A. M., & Draghia, R. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.1085 · Cited by 58
Charbonnier, S., Nominé, Y., Ramírez, J., Luck, K., Chappelle, A., Stote, R. H., Travé, G., Kieffer, B., & Atkinson, R. A. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.015 · Cited by 57
MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2
Fujii, T., Shimada, K., Asano, A., Tatsumi, Y., Yamaguchi, N., Yamazaki, M., & Konishi, N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081351 · Cited by 57
Inturi, R., & Jemth, P. (2021) · Virology · doi:10.1016/j.virol.2021.07.005 · Cited by 56
Chen, H., Zhang, W., Cheng, X., Guo, L., Xie, S., Yuan-fang Ma, A., Guo, N., & Shi, M. (2017) · Cancer Science · doi:10.1111/cas.13275 · Cited by 56
Blochin, E., Park, K. J., Tickoo, S. K., Reuter, V. E., & Al‐Ahmadie, H. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.112 · Cited by 54
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
Shibata, T., Lieblong, B. J., Sasagawa, T., & Nakagawa, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.07.001 · Cited by 54
The E6 Oncoprotein from HPV16 Enhances the Canonical Wnt/β-Catenin Pathway in Skin Epidermis In Vivo
Bonilla-Delgado, J., Bulut, G., Liu, X., Cortés-Malagón, E. M., Schlegel, R., Flores-Maldonado, C., Contreras, R. G., Chung, S.-H., Lambert, P. F., Üren, A., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0287 · Cited by 50
The Roles of HK2 on Tumorigenesis of Cervical Cancer
Liu, C., Wang, X., & Zhang, Y. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819871306 · Cited by 52
Yu, Y., Zhang, Y., & Zhang, S. (2013) · Oncology Letters · doi:10.3892/ol.2013.1404 · Cited by 51
Viral infections and breast cancer – A current perspective
Gannon, O. M., Antonsson, A., Bennett, I., & Saunders, N. A. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.076 · Cited by 51
PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
Huang, W., Liu, J., Xu, K. L., Chen, H., & Bian, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.849352 · Cited by 51
Dermatologic manifestations of HPV in HIV-infected individuals
Gormley, R. H., & Kovarik, C. (2009) · Current HIV/AIDS Reports · doi:10.1007/s11904-009-0018-8 · Cited by 50
Immune responses to human papillomavirus infection and vaccination
Kiamba, E. W., Goodier, M. R., & Clarke, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591297 · Cited by 49
Human papillomavirus infection in lung and esophageal cancers: Analysis of 485 Asian cases
Goto, A., Li, C., Ota, S., Niki, T., Ohtsuki, Y., Kitajima, S., Yonezawa, S., Koriyama, C., Akiba, S., Uchima, H., et al. (2011) · Journal of Medical Virology · doi:10.1002/jmv.22150 · Cited by 49
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Pfannenstiel, L. W., Diaz-Montero, C. M., Tian, Y. F., Scharpf, J., Ko, J. S., & Gastman, B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0054 · Cited by 49
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Wang, Y., & Li, G. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0674-4 · Cited by 49
Metadata
- Authors
- Narisawa‐Saito, M., & Kiyono, T.
- Affiliations
- National Cancer Center Research Institute (JP)
- Corresponding author
- Kiyono, Tohru
- ORCID
- Kiyono, Tohru
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2007-07-23
- Volume
- 98
- Issue
- 10
- Pages
- 1505-1511
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- PMC
- PMC11158331
- OpenAlex
- W2011499737
- Cited by
- 528
- References
- 85
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 46 · 2023: 24 · 2022: 33 · 2021: 43 · 2020: 32 · 2019: 24 · 2018: 36 · 2017: 27 · 2016: 23 · 2015: 25 · 2014: 25 · 2013: 26 · 2012: 27
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- human papillomavirus, HPV16, HPV 18, cervical cancer, carcinogenesis, E6 oncoprotein, E7 oncoprotein, p53 degradation, UBE3A, retinoblastoma protein, E2F transcription factors, viral oncogenesis, HPV vaccine
- MeSH terms
- Cell Transformation, Neoplastic, Cell Transformation, Viral, Uterine Cervical Neoplasms, Female, Humans, Oncogene Proteins, Viral, Repressor Proteins, Papillomaviridae, Papillomavirus Infections, Papillomavirus E7 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
